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Abstract
Aims/hypothesis By genome-wide association meta-analysis, 17 genetic loci associated with fasting serum insulin (FSI), a
marker of systemic insulin resistance, have been identified. To define potential culprit genes in these loci, in a cross-sectional
study we analysed white adipose tissue (WAT) expression of 120 genes in these loci in relation to systemic and adipose tissue
variables, and functionally evaluated genes demonstrating genotype-specific expression in WAT (eQTLs).
Methods Abdominal subcutaneous adipose tissue biopsies were obtained from 114 women. Basal lipolytic activity was mea-
sured as glycerol release from adipose tissue explants. Adipocytes were isolated and insulin-stimulated incorporation of
radiolabelled glucose into lipids was used to quantify adipocyte insulin sensitivity. Small interfering RNA-mediated knockout
in human mesenchymal stem cells was used for functional evaluation of genes.
Results Adipose expression of 48 of the studied candidate genes associated significantly with FSI, whereas expression of 24, 17
and 2 genes, respectively, associatedwith adipocyte insulin sensitivity, lipolysis and/orWATmorphology (i.e. fat cell size relative
to total body fat mass). Four genetic loci contained eQTLs. In one chromosome 4 locus (rs3822072), the FSI-increasing allele
associated with lower FAM13A expression and FAM13A expression associated with a beneficial metabolic profile including
decreasedWAT lipolysis (regression coefficient, R = −0.50, p = 5.6 × 10−7). Knockdown of FAM13A increased lipolysis by ~1.5-
fold and the expression of LIPE (encoding hormone-sensitive lipase, a rate-limiting enzyme in lipolysis). At the chromosome 7
locus (rs1167800), the FSI-increasing allele associated with lower POM121C expression. Consistent with an insulin-sensitising
function, POM121C expression associated with systemic insulin sensitivity (R = −0.22, p = 2.0 × 10−2), adipocyte insulin sensi-
tivity (R = 0.28, p = 3.4 × 10−3) and adipose hyperplasia (R = −0.29, p = 2.6 × 10−2). POM121C knockdown decreased expres-
sion of all adipocyte-specific markers by 25–50%, suggesting that POM121C is necessary for adipogenesis.
Conclusions/interpretation Gene expression and adipocyte functional studies support the notion that FAM13A and POM121C
control adipocyte lipolysis and adipogenesis, respectively, and might thereby be involved in genetic control of systemic insulin
sensitivity.
Keywords Genomics . Insulin sensitivity . Lipidmetabolism
Tweet The genes FAM13A and POM121C might be involved in genetic
control of systemic insulin sensitivity in humans by controlling abdominal
adipocyte function #genomics #GWAS
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Abbreviations
eQTL Expression quantitative trait locus
FDR False discovery rate
FPG Fasting plasma glucose
FSI Fasting serum insulin
FSIadjBMI FSI adjusted for BMI
GWAS Genome-wide association study
hMSC Human mesenchymal stem cell
IR Insulin resistance
LD Linkage disequilibrium
siRNA Small interfering RNA
WAT White adipose tissue
WHRadjBMI WHR adjusted for BMI
Introduction
Insulin resistance (IR), wherein cellular responses to insulin
are impaired, is a key component of type 2 diabetes and is also
implicated in the development of cardiovascular disease [1].
IR is associated with metabolic disturbances in liver, skeletal
muscle and white adipose tissue (WAT) and is characterised
by hyperinsulinaemia, hyperglycaemia and dyslipidaemia.
Fasting serum insulin (FSI) has been shown to correlate with
the gold standard for assessing IR, namely euglycaemic insu-
lin clamp, and is therefore used as a simple proxy for insulin
sensitivity in various studies [2].
Abdominal obesity and a state of overweight are strong risk
factors for systemic IR [3]. Abdominal obesity is associated
with altered cytokine and adipokine release from WAT, which
is linked to low-grade inflammation and systemic IR [4]. In
addition, adipose morphology is central to IR and development
of type 2 diabetes [5, 6]. WAT can expand by increasing the
number and/or volume of adipocytes causing distinct adipose
morphologies termed hyperplasia (many small adipocytes) or
hypertrophy (few large adipocytes). Hypertrophic adipose tis-
sue is associated with a pernicious metabolic profile, with
blunted ability of insulin to stimulate fat synthesis through glu-
cose conversion into lipids (lipogenesis), leading to an influx of
NEFA into the liver and to systemic IR [7, 8]. The lipolytic
activity in adipose tissue, resulting in the release of NEFA, can
also influence insulin sensitivity, as reviewed [9].
Despite these findings, it is still to a large extent unclear
how IR develops and only about 25% of obese women are
insulin resistant [10]. One explanation is varying genetic
predisposition; genome-wide association studies (GWAS)
have identified 17 SNPs associated with FSI and/or FSI
adjusted for BMI (FSIadjBMI) [11]. With the aim of defining
culprit genes in these loci, and the mechanisms by which they
may directly predispose to IR, we herein analysed WAT
expression of 120 genes in these loci in relation to FSI and
adipocyte phenotypes related to IR (morphology, insulin-
stimulated lipogenesis, lipolysis). We also performed in silico
expression quantitative trait locus (eQTL) analysis and
selected genes demonstrating genotype-specific expression
in WAT for functional analysis by small interfering RNA
(siRNA) knockdown followed by evaluation of adipocyte-
specific genes and glycerol release.
Methods
Participants The study included 114 Swedish non-diabetic
women with WAT global transcriptome profile available from
a previous study [12]. The women were recruited by adver-
tisement from the general adult population in the Stockholm
(Sweden) area (Table 1). They displayed a large inter-
individual variation in BMI and were healthy, except that
Research in context 
What is already known about this subject? 
Numerous genetic loci associated with fasting insulin as a measure of insulin resistance have been identified 
What is the key question? 
Can specific candidate genes in these genetic loci be linked to adipocyte variables, thus linking adipose function to
systemic insulin resistance?  
What are the new findings? 
FAM13A is a candidate gene for fasting insulin and might protect against insulin resistance by inhibiting lipolysis 
POM121C is another candidate gene that might protect against insulin resistance by promoting adipogenesis 
How might this impact on clinical practice in the foreseeable future? 
FAM13A and POM121C should be evaluated as therapeutic targets for type 2 diabetes-associated insulin resistance
•
•
•
•
•
Diabetologia
some were obese. The study was approved by the regional
ethics board in Stockholm and written informed consent was
obtained from each participant. The experiments conformed
to the principles set out in the WMA Declaration of Helsinki
and the Department of Health and Human Services Belmont
Report. Participants were investigated at 08:00 hours after an
overnight fast in a university clinic. Anthropometric measure-
ments (height, weight, waist and hip circumference, blood
pressure) were performed followed by venous blood sam-
pling. WHR adjusted for BMI (WHRadjBMI) was calculated
in a sex-specific manner by inverse-normal transformation of
the residuals of the linear regressionmodel:WHR adjusted for
age, age2 and BMI [13]. Fasting plasma glucose (FPG) and
lipids were analysed at the hospital’s routine chemistry labo-
ratory. Plasma insulin was measured by ELISA (Mercodia,
Uppsala, Sweden) as previously described [14]. The
Mercodia Diabetes Antigen Control (10-1134-01/10-1164-
01) was included as control in all ELISA runs; samples were
visually inspected before each run and no sample showed
signs of haemolysis.
Following the clinical examination, an abdominal subcuta-
neous WAT biopsy was obtained by needle aspiration, as de-
scribed [15]. All WAT samples were rapidly rinsed in sodium
chloride (9 mg/ml) and specimens of 300 mg unfractionated
WAT were immediately frozen in liquid nitrogen for subse-
quent RNA isolation. Remaining tissue was used immediately
for cell culture experiments as described below. No follow-up
of participants was performed.
WAT experiments The adipose tissue was brought to the lab-
oratory, rinsed repeatedly in saline (154 mmol/l NaCl) and
visible blood vessels and cell debris were removed. Adipose
tissue specimens (about 1 g) were divided into portions, one of
which was treated with collagenase to obtain isolated adipo-
cytes as described [16]. The mean weight and volume of these
cells were determined as previously described [17, 18]. A
curve fit of the relationship between mean adipocyte volume
and total fat mass was performed as previously reported to
assess adipose tissue morphology [19]. The difference be-
tween the measured and the expected fat cell volume obtained
from the mean curve fit at the corresponding fat mass deter-
mines adipose morphology. If the measured fat cell volume is
larger than expected, adipose hypertrophy prevails, whereas
the opposite is valid for hyperplasia. These values, which can
be quantitatively assessed, were obtained from the calcula-
tions made previously [19].
Spontaneous unstimulated lipolytic activity was deter-
mined in adipose tissue explants as described [20]. In brief,
pieces of adipose tissue (200 or 300 mg) were incubated for
2 h (100 mg/ml) at 37°C with air as the gas phase in Krebs–
Ringer phosphate buffer (pH 7.4) supplemented with glucose
(8.6 mmol/l), ascorbic acid (0.1 mg/ml) and bovine serum
albumin (20 mg/ml). Glycerol release into the medium was
measured using a sensitive bioluminescence method and
expressed as amount of glycerol released per 2 h and 107
adipocytes.
Adipocyte lipogenesis was determined as described [21].
In brief, isolated adipocytes were incubated in vitro in an
albumin-containing buffer with [3H]glucose (5 × 105 dpm/
ml), unlabelled glucose (0.001 mmol/l) and varying concen-
trations (0–70 nmol/l) of human insulin (I 2643, Sigma-
Aldrich, Stockholm, Sweden). The incubations were conduct-
ed for 2 h at 37°C with air as the gas phase. Incubations were
stopped by rapidly chilling the incubation vials to 4°C.
Thereafter, incorporation of radiolabelled glucose into adipo-
cyte lipids was determined; this reflects lipogenesis and was
expressed as the amount of glucose incorporated per adipo-
cyte number, as described previously [21]. Values at the max-
imum effective insulin concentration are reported.
Microarray data Global transcriptome profiles of WAT from
the clinical cohort were assessed by Gene 1.0 or 1.1 ST
Affymetrix arrays and has been reported earlier [12]. In this
study we limited the analysis to candidate genes for FSI or
FSIadjBMI listed in Scott et al [11], as well as genes ±500 Kb
of the tag-SNPs. Genome information was extracted from
SNPPER (http://snpper.chip.org/bio/snpper-enter) using
genome build 38 (accessed 9 August 2016). Ingenuity
Pathway Analysis (https://www.qiagenbioinformatics.com/)
was used for network analysis (accessed 18 September
2017). SNPnexus (http://snp-nexus.org/) was used for SNP
annotation (accessed 10 June 2017) [22]. GTEx database
(https://www.gtexportal.org/home/) was used to identify
WAT eQTLs (accessed 28 August 2016).
Table 1 Characteristics of 114 examined women
Characteristic Means±SD
Age, years 43 ± 11
BMI, kg/m2 34 ± 9
FPG, mmol/l 5.17 ± 0.65
FSI, pmol/l 63 ± 50
HOMA-IR 0.96 ± 2.12
Fasting plasma total cholesterol, mmol/l 4.9 ± 0.9
Fasting plasma HDL-cholesterol, mmol/l 1.4 ± 0.4
Fasting plasma triacylglycerols, mmol/l 1.3 ± 0.8
Fat cell volume, pl 731 ± 266
WAT morphologya, plb 17 ± 165
Basal lipolysisc, μmol glycerol (2 h)−1 (107 adipocytes)−1 4.26 ± 2.62
Insulin-stimulated lipogenesisd, nmol of glucose (2 h)−1
(107 adipocytes)−1
4.71 ± 6.22
a Data were missing from 11 women
bDefined in the ‘WAT experiments’ section of the Methods
c Data were missing from 22 women
dData were missing from five women
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Adipocyte cell culture and small interfering RNA transfection
Isolation, growth and differentiation of human mesenchymal
stem cells (hMSCs) were carried out as previously described
[23]. hMSCs at day 4 of differentiation were transfected using
a Neon electroporator (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s protocol. Briefly, 1,000,000
hMSCs were mixed with 40 nmol/l ON-TARGETplus
SMARTpool small interfering RNAs (siRNAs) targeting
POM121C, UHRF1BP1, SNRPC and FAM13A or non-
targeting siRNA pool (Dharmacon, Lafayette, CO, USA)
and electroporated using 100 μl Neon electroporation tip.
Electroporation conditions were 1600 V, 20ms width, 1 pulse.
Electroporation was repeated until the required number of
cells was collected for a certain experimental set-up.
Following electroporation, the cells were plated in antibiotic-
free medium at a density of 220,000 cells/well in 24-well
plates. Medium was replaced 24 h post-transfection. The cells
were cultured until day 7 or 12 of differentiation, at which
time the medium and RNAwere collected. hMSCs were also
reverse transfected 24 h before induction of adipogenesis
using ON-TARGETplus SMARTpool siRNAs targeting
FAM13A or non-targeting siRNA pool (Dharmacon) as previ-
ously described [24].
Quantitative RT-PCRWAT specimens (100 mg) from the clin-
ical samples were disrupted mechanically and RNA isolated
using the RNeasy kit (Qiagen, Manchester, UK) according to
the manufacturer’s instructions. The hMSCs were collected
on days 7 and 12 after the induction of differentiation for
isolation of RNA. Total RNA from the hMSCs cultures
was extracted using NucleoSpin RNA II kit (Macherey-
Nagel, Düren, Germany). The concentration and purity of
RNA were measured using a Nanodrop ND-1000
Spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA). Reverse transcription was performed using the
iScript cDNA synthesis kit (Qiagen) and random hexamer
primers (Invitrogen). Quantitative RT-PCR was performed
using commercial TaqMan probes (Thermo Fisher
Scientific). Gene expression in the clinical cohort was nor-
malised to the internal reference gene LRP10, and in the cell
culture experiments to 18S. Relative expression was calcu-
lated using the 2−ΔCt method [25].
Glycerol measurements Glycerol in media was measured
using Free Glycerol Reagent (Sigma Aldrich, St Louis,
MO, USA) and Amplex UltraRed (Invitrogen), according
to the manufacturers’ instructions. Amplex Ultra Red was
diluted 100-fold in Free Glycerol Reagent, mixed with
20 μl of conditioned medium in a 96-well plate, and
incubated at room temperature for 15 min. Fluorescence
was measured (excitation/emission wavelengths 530 nm /
590 nm) using an Infinite M200 plate reader (Tecan
Group, Männedorf, Switzerland).
Statistical analysis FSI, lipolysis and lipogenesis measure-
ments were log10 transformed before analysis to obtain nor-
mally distributed variables. Microarray results from the clini-
cal cohort were analysed by regression in QLUCORE version
3.2 (www.qlucore.com), adjusting for array batch and, as
indicated, age. Phenotypes correlating with BMI (i.e. FSI,
FPG, insulin-stimulated lipogenesis and lipolysis) were
analysed both without and with BMI as covariates, as speci-
fied. False discovery rate (FDR) was used to adjust for the
analysis of multiple genes. FDR <5% was considered signif-
icant. Quantitative RT-PCR results and clinical variable were
analysed by regression in JJMP v. 11 (www.jmp.com). Results
of in vitro experiments were analysed by paired t test.
Results
FSI and adipose traits The cohort characteristics are shown in
Table 1. The studied women displayed a wide variation in
BMI and FSI. As expected, BMI was positively correlated
with FSI (r2 = 0.48, p = 2.0 × 10−17) (Fig. 1a). BMI was also
positively correlated with adipose spontaneous lipolysis
(r2 = 0.15, p = 0.0002) and inversely correlated with
insulin-stimulated lipogenesis (r2 = 0.08; p = 0.0038) (results
not shown). There was no significant association with adi-
pose morphology. FSI was positively correlated with adipose
morphology (r2 = 0.15, p = 2.0 × 10−5) and spontaneous li-
polysis (r2 = 0.23, p = 1.5 × 10−6) but was negatively corre-
lated with insulin-stimulated lipogenesis (r2 = 0.06, p =
0.0088) (Fig. 1b–d). Associations between FSI and morphol-
ogy (p = 1.3 × 10−6) or spontaneous lipolysis (p = 0.0019)
remained significant in a multiple regression including
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Fig. 1 Relationship between FSI and BMI (a), adipose morphology
(b), insulin-stimulated lipogenesis (c) and basal lipolysis (d). n = 114
women. Defined in the ‘WAT experiments’ section of the Methods.
Linear regression was used in all analyses
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BMI as independent variable. There was no influence of age
on the examined variables (results not shown).
Expression of candidate genes for FSI in relation to adipose
traitsWe next examined whether WAT expression of genes in
loci robustly associated with FSI and FSIadjBMI were asso-
ciated with clinical or adipose phenotypes related to IR. There
were 135 protein-coding transcripts in the 17 FSI- and
FSIadjBMI-associated loci (ESM Table 1) and expression of
120 of these transcripts were quantified by array. We did not
analyse non-coding transcripts since microRNAs were not
enriched in the total prepared RNA from WAT, and other
non-coding transcripts and RNAs were not represented with
probes on the arrays. Expression of 56 genes was associated
with BMI (FDR <5%) (Table 2 and ESM Table 2) but only
one gene was associated with WHR. The expression of 48
genes was associated with FSI, of which 11 remained nomi-
nally significant after adjustment for BMI, whereas 19 genes
were associated with FPG, of which two remained nominally
significant after adjustment for BMI.
For WAT variables, 24 genes were associated with insulin-
stimulated lipogenesis (FDR <5%); five of these genes
remained nominally significant after adjustment for BMI.
Expression of 17 genes was associated with spontaneous li-
polysis and four remained significant after adjusting for BMI.
Only two genes were associated with adipose morphology
(Table 2, ESM Table 2). Expression of four genes was corre-
lated with age (i.e. GSTCD, IRS1, SCN3A and TIMP4); how-
ever, adjustment for age did not affect the relationship be-
tween expression of these genes and FSI or adipose pheno-
types (results not shown). Expression of three genes whose
expression associated with FSI was validated by quantitative
RT-PCR using RNA from subcutaneousWATobtained from a
previously examined cohort of 55women (ESMTable 3) [26].
Results were directionally consistent between microarray and
quantitative RT-PCR for all three genes and analysed pheno-
types, except for the association between insulin-stimulated
lipogenesis and ARL15 expression levels.
Network analysis The 48 genes whose expression related to
FSI, 24 genes related to insulin-stimulated lipogenesis and
17 genes related to lipolysis were analysed in Ingenuity
Pathway Analysis. The genes associated with insulin-
stimulated lipogenesis were enriched in several signalling
pathways, including activation of NF-κB and MAPK sig-
nalling (ESM Table 4). These results were related to altered
expression of PPARG, IRS1, ITGA2, RAF1 and MAP3K1.
Interestingly, the same signalling pathways, including
NF-κB activation, were also enriched among FSI-
associated genes; the genes mentioned above also contrib-
uted to the results for FSI (ESM Table 5). The lipolysis-
associated genes were linked to a different set of pathways
(results not shown). Network analysis provide little
evidence of connection between genes associated with
insulin-stimulated lipogenesis or lipolysis (ESM Figs 1,
2). PPARG was the only FSI-associated gene with several
indirect connections to other FSI-associated genes,
pointing to a weak functional connection between FSI-
associated genes (ESM Fig. 3). Bearing this in mind, we
continued to evaluate the SNPs and candidate genes for
FSI one at a time.
Linking candidate genes for FSI to WAT function by eQTL
analysis and siRNA knockdown To further link candidate
genes from GWAS to WAT function, we used in silico analy-
sis to determine whether tag-SNPs for each of the 17 FSI- or
FSIadjBMI-associated loci (ESM Table 1) comprised cis
eQTLs. According to GTEx, eight genes in four different ge-
netic loci demonstrate genotype-specific expression (Table 3).
At three of these loci, WAT gene expression associated with
FSI and adipose phenotypes (FDR <5%). At the fourth locus,
UHRF1BP1 was nominally associated with adipose morphol-
ogy. According to the SNP annotation tool SNPnexus, three of
the SNPs are intronic and the fourth intergenic (Table 3). None
of the SNPs has any regulatory function ascribed to them.
Four genes comprising eQTLs (FAM13A, UHRF1BP1,
POM121C and SNPRC) were taken forward for functional
evaluation in hMSCs to determine possible impact on adipo-
cyte function. We first evaluated expression of the four genes
during differentiation of hMSCs. The expression of FAM13A
increased directly after induction of differentiation, whereas
the expression of POM121C, UHRF1BP1 and SNRPC
displayed detectable increases only at day 8 (Fig. 2). Based
on these data, the genes were knocked down using siRNA in
the hMSCs at day 4, corresponding to an early stage of differ-
entiation. Three and eight days post-transfection (i.e. day 7
and 12 of differentiation), this resulted in a decreased expres-
sion of FAM13A, UHRF1BP1 and SNPRC by 70–95% and
decreased expression of POM121C by 60% (Fig. 3).
Expression levels of adipocyte-enriched genes central to
adipogenesis (PPARG, CEBPA), lipolysis (LIPE) and insulin
sensitivity (SLC2A4,ADIPOQ) weremeasured in each knock-
down experiment. Knockdown of FAM13A increased expres-
sion of LIPE, SLC2A4, PPARG and CEBPA (Fig. 3a). We also
evaluated levels of glycerol in the conditioned medium as a
marker for lipolysis. Glycerol levels increased significantly,
by approximately 1.5-fold, indicating an increased lipolysis
(Fig. 4). As FAM13A expression increased from the very be-
ginning of differentiation, we also knocked down FAM13A
one day prior to induction of differentiation (day −1) and this
had a similar effect on adipocyte-specific gene expression
(results not shown). POM121C knockdown resulted in signif-
icantly reduced expression of all investigated genes (Fig. 3b)
and reduced glycerol release (Fig. 4). Knockdown of SNRPC
resulted in strongly reduced expression of ADIPOQ and
SLC2A4, as well as modestly decreased expression of LIPE
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and CEBPA (Fig. 3c). The glycerol level in the medium was
significantly reduced, which is in line with gene expression
data (Fig. 4).UHRF1BP1 knockdown resulted in a temporary
and modest increase in the expression of PPARG and CEBPA,
with no effect on glycerol release in medium. Four eQTL
genes were excluded from the functional evaluation in vitro:
IRS1 because its function is already defined; PMS2P3,
TRIM73 and STAG3L1 since commercial siRNAs reagents
were unavailable, or because the genes were expressed at
low levels in adipocytes or below the detection threshold in
WAT.
Discussion
To explore the role of WAT in the genetic predisposition to
systemic IR we have analysed adipose expression of 120 can-
didate genes in genetic loci associated with FSI and
FSIadjBMI.We report that adipose expression of a surprising-
ly high number of these genes (48; 40%) associate with FSI
and with fat cell insulin sensitivity or lipolysis (35; 30%).
These findings give support to the notion that WAT is an
important organ mediating the effects of genetic variants on
FSI. Furthermore, functional analysis in vitro by siRNA-
mediated knockdown highlighted FAM13A and POM121C
as potential causal links between SNPs and IR at specified
GWAS loci. None of these genes have to our knowledge pre-
viously been implicated in WAT function in humans.
At one chromosome 4 locus (rs3822072), the FSI-
associated allele is associated with lower FAM13A expression.
Consistent with a protective role of FAM13A on IR, we show
that FAM13A expression is associated with a beneficial meta-
bolic profile, including decreased WAT lipolysis, and that
FAM13A knockdown increases lipolysis and expression of
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Fig. 3 Expression of FAM13A (a), POM121C (b), SNRPC (c) and
UHRF1BP1 (d) was knocked down using siRNA in hMSCs in vitro at
day 4 of differentiation until day 7 and 12 of differentiation, upon which
the expression of target and ADIPOQ, CEBPA, SLC2A4, LIPE and
PPARG was monitored. We have performed three biological experiments
with 3–4 technical replicates in each experiment; n = 11 technical
replicates for NegC; n = 12 technical replicates for target genes. Results
were analysed using the paired t test and are presented as relative fold
change±SD vs negative control (NegC) at each time point during differ-
entiation. Black bars, day 7; white bars, day 12. *p < 0.05, **p < 0.01 and
***p < 0.001 vs NegC
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7 8 9 10 11 12
R
e
la
ti
v
e
 g
e
n
e
 e
x
p
r
e
s
s
io
n
Day of differentiation
*
**
**
*
***
**
**
* **
*
*
**
Fig. 2 Gene expression of FAM13A, POM121C, SNRPC and
UHRF1BP1 were monitored using quantitative RT-PCR during differen-
tiation of hMSCs to adipocytes in vitro from start of differentiation (day
0) until day 12. POM121C (solid blue line), FAM13A (dotted black line),
UHRF1BP1 (dashed black line) and SNRPC (dashed grey line). Results
were analysed using the paired t test and are presented as relative fold
change+SD vs day 0. *p < 0.05, **p < 0.01 and ***p < 0.001 vs day 0
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LIPE, which is a rate-limiting enzyme in lipolysis [27]. We
previously showed that basal lipolytic activity is a strong deter-
mination of insulin sensitivity [20]. The increased expression of
other genes with central functions in adipogenesis and adipo-
cytes (e.g. PPARG, CEBPA and SLC2A4) following FAM13A
knockdown indicate that FAM13A has the potential to inhibit
adipogenesis; however, the clinical relevance of this finding is
unclear. The precise molecular mechanisms linking FAM13A to
lipolysis are unknown. FAM13A has previously been reported
to induce fatty acid oxidation, autophagia via activation of Akt
and β-catenin degradation in various cell types [28–30]. Akt
controls lipolysis [31] and could hypothetically be involved in
FAM13A inhibition of lipolysis; however, detailed mechanistic
studies are beyond the scope of this investigation.
At the chromosome 7 locus (rs1167800), the FSI-
associated allele is associated with lower POM121C expres-
sion. Consistent with an insulin-sensitising function,
POM121C expression is positively associated with systemic
and adipocyte insulin sensitivity and with adipose hyperpla-
sia. Adipose hypertrophy has previously been linked to im-
paired adipogenesis and IR [8]. POM121C knockdown early
in the adipogenesis caused decreased expression of all
adipocyte-specific markers suggesting that POM121C is nec-
essary for adipocyte differentiation. We observed reduced
glycerol release following POM121C knockdown. This is
probably secondary to impaired adipogenesis (i.e. without
functional adipocytes there is no lipolysis). POM121C en-
codes a nucleoporin and forms an important component of
the nuclear pore complexes [32]; it has to our knowledge
previously not been implicated in human metabolic disease.
At one chromosome 6 locus (rs6912327), the effects ob-
served after siRNA-mediated knockdown of SNRPC and
UHRF1BP1 did not suggest that these genes underlie genetic
control of FSI at this locus. Thus, the FSI-associated allele is
associated with higher SNPRPC expression, suggesting that
SNRPC contributes to metabolic disease. However, SNPRPC
knockdown reduced expression of ADIPOQ, encoding the
insulin-sensitising hormone adiponectin, and SLC2A4,
encoding the glucose transporter GLUT4; these findings are
consistent with an insulin-sensitising function of SNRPC.
Lipolysis was also reduced, potentially secondary to impaired
lipid accumulation. Knockdown of UHRF1BP1 had marginal
effects on adipocyte markers, suggesting that UHRF1BP is
not a causative gene for FSI. Of note, expression of neither
UHRF1BP nor SNPRPC was associated with WAT variables
with FDR <5%.
The present study has several limitations. The investigated
genomic regions are based on distance and not linkage dis-
equilibrium (LD) patterns and we cannot exclude that genes
with more distal cis-eQTL effects might play a role in WAT
function. To our knowledge, however, no reliable LD data are
available for this Swedish population. Furthermore, in
Ensemble (www.ensemble.org, accessed 22 November
2017) we did not find any non-synonymous, or otherwise
likely functional, SNPs in high LD (r2 ≥ 0.9) with rs3822072
or rs1167800. Another limitation is that we studied women
only and our results cannot be generalised to the entire
population. The analysis was limited to abdominal
subcutaneous WAT and the results, thus, cannot be
generalised to other WAT depots. The relative importance of
subcutaneous vs visceralWAT for IR is debatable. It is notable
that removal of the greater omentum in addition to bariatric
surgery is not associated with metabolic benefits after long-
term follow-up, pointing to the limited importance of visceral
WAT for metabolic disease in this population [33].
Only a few of the candidate genes for FSI shown in Table 2
were taken forward for functional evaluation. Beyond
FAM13A and POM121C, however, a few of the genes in
Table 2 have functions ascribed to them which support the
notion that they might influence the metabolic function of
WAT and systemic IR: PPARG and IRS1 control adipogenesis
and insulin signalling, respectively [34, 35]; MAP3K1 and
TCF7L2 are involved in Wnt signalling [36, 37], which in-
hibits adipogenesis;GRB14 is directly involved in insulin sig-
nalling [38] and ARL15 is encoded in a major genetic locus
controlling adiponectin levels [39]. However, information
about function is lacking for most of the genes in Table 2,
making it difficult to define networks based on functional
connectivity between the genes.
Many genetic variants seem to have pleiotropic effects on
metabolic traits [11]. The genetic locus on chromosome 4
harbouring FAM13A has previously been linked to body fat
distribution [40], and the chromosome 7 locus harbouring
POM121C has been linked to BMI [41]. Thus, it is possible
that the impact of these genes on lipolysis and adipogenesis is
important for development of obesity as well. At the same
time, the observation that several of the examined genes are
0
0.5
1.0
1.5
2.0
R
e
la
ti
v
e
 g
ly
c
e
r
o
l
(
s
ig
e
n
e
/s
iN
e
g
C
)
* *
*
***
***
*
si
N
eg
C
si
F
A
M
1
3
A
si
P
O
M
1
2
1
C
si
U
H
R
F
1
B
P
1
si
S
N
R
P
C
Fig. 4 Expression of FAM13A, POM121C, SNRPC and UHRF1BP1
was knocked down using siRNA in hMSCs in vitro and glycerol levels in
conditional medium were evaluated. We have performed 3 biological
experiments with 3–4 technical replicates in each experiment; n = 11
technical replicates for NegC; n = 12 technical replicates for target genes.
Results were analysed using the paired t test and are presented as relative
fold change±SD vs non-targeting siRNA pool (siNegC). Black bars, day
7; white bars, day 12. *p < 0.05 and ***p < 0.001 vs NegC
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associated with more than one studied phenotype emphasizes
the functional connection between studied phenotypes (e.g.
large fat cells are insulin resistant and display enhanced spon-
taneous lipolysis [8]).
In conclusion, gene expression and adipocyte functional
studies support the notion that FAM13A and POM121C con-
trol adipocyte lipolysis and adipogenesis, respectively, and
might thereby be involved in genetic control of systemic in-
sulin sensitivity and, possibly, fat accumulation.
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